Tonix Pharmaceuticals is enrolling participants in a Phase 3 trial for fibromyalgia, the RALLY study.
For more information, please visit www.RALLYStudy.com or www.clinicaltrials.gov (NCT04508621).

News / Press Releases

: Press Releases

Press Releases

Tonix Pharmaceuticals Regains Compliance with NASDAQ Minimum Bid Price Requirement

December 18, 2018 • 7:00 AM EST

Tonix Pharmaceuticals Announces Closing of $15,000,000 Public Offering

December 11, 2018 • 4:00 PM EST

Tonix Pharmaceuticals Prices $15,000,000 Public Offering

December 7, 2018 • 10:35 AM EST

Tonix Pharmaceuticals Announces Additional Details of the New Phase 3 Study of Tonmya® for PTSD, Following Receipt of FDA Minutes

November 29, 2018 • 7:00 AM EST

Tonix Pharmaceuticals Announces 1-for-10 Reverse Stock Split

November 27, 2018 • 7:00 AM EST

Tonix Pharmaceuticals Reports Third Quarter 2018 Financial Results and Operational Highlights

November 9, 2018 • 7:30 AM EST

Tonix Pharmaceuticals Announces New Patent Coverage Protecting Tonmya®

November 7, 2018 • 7:00 AM EST

Tonix Pharmaceuticals Presented Results and Retrospective Analyses of Phase 3 P301 “HONOR” Study in Poster Presentation at CNS Summit 2018

November 6, 2018 • 7:00 AM EST

Tonix Pharmaceuticals to Present at BIO-Europe International Partnering Conference

November 1, 2018 • 7:00 AM EDT

Tonix Pharmaceuticals Announces Innovative Design in Next Phase 3 Study of Tonmya® for PTSD, Following FDA Meeting

October 31, 2018 • 7:00 AM EDT

Show All

News / Press Releases : Press Releases